These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36471318)

  • 1. Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis.
    Rheinheimer S; Christopoulos P; Erdmann S; Saupe J; Golpon H; Vogel-Claussen J; Dinkel J; Thomas M; Heussel CP; Kauczor HU; Heussel G
    BMC Med Imaging; 2022 Dec; 22(1):215. PubMed ID: 36471318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer.
    Ippolito D; Drago SG; Pecorelli A; Maino C; Querques G; Mariani I; Franzesi CT; Sironi S
    World J Gastroenterol; 2020 May; 26(20):2657-2668. PubMed ID: 32523318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
    Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
    Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy.
    Xu L; Ge X; Sun N; Liu X
    Acta Radiol; 2020 Oct; 61(10):1316-1325. PubMed ID: 32053003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases.
    Shukla-Dave A; Lee NY; Jansen JF; Thaler HT; Stambuk HE; Fury MG; Patel SG; Moreira AL; Sherman E; Karimi S; Wang Y; Kraus D; Shah JP; Pfister DG; Koutcher JA
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1837-44. PubMed ID: 21601373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
    Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
    Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
    Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Dynamic-Enhanced MRI and Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Prediction of the Pathological Response to Neoadjuvant Chemotherapy and the Prognosis in Locally Advanced Gastric Cancer.
    Zhu Y; Jiang Z; Wang B; Li Y; Jiang J; Zhong Y; Wang S; Jiang L
    Front Oncol; 2022; 12():841460. PubMed ID: 35425711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
    Guo W; Zhang Y; Luo D; Yuan H
    Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
    [No Abstract]   [Full Text] [Related]  

  • 12. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.
    Chen BB; Hsu CY; Yu CW; Liang PC; Hsu C; Hsu CH; Cheng AL; Shih TT
    Eur Radiol; 2017 Jul; 27(7):3069-3079. PubMed ID: 27957638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients.
    Wu G; Huang W; Xu J; Li W; Wu Y; Yang Q; Liu K; Zhu M; Balasubramanian PS; Li M
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1771-1780. PubMed ID: 34398299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
    J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging.
    Zheng D; Yue Q; Ren W; Liu M; Zhang X; Lin H; Lai G; Chen W; Chan Q; Chen Y
    Magn Reson Imaging; 2017 Jan; 35():125-131. PubMed ID: 27587228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxelwise comparison of perfusion parameters estimated using dynamic contrast enhanced (DCE) computed tomography and DCE-magnetic resonance imaging in locally advanced cervical cancer.
    Kallehauge J; Nielsen T; Haack S; Peters DA; Mohamed S; Fokdal L; Lindegaard JC; Hansen DC; Rasmussen F; Tanderup K; Pedersen EM
    Acta Oncol; 2013 Oct; 52(7):1360-8. PubMed ID: 24003852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
    Vivoda Tomšič M; Korošec P; Kovač V; Bisdas S; Šurlan Popovič K
    BMC Cancer; 2022 Feb; 22(1):191. PubMed ID: 35184730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.
    Chen BB; Shih TT
    World J Gastroenterol; 2014 Mar; 20(12):3125-34. PubMed ID: 24695624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
    Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
    Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.